Telix Pharmaceuticals Limited (TLX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $7.52
• Market Cap: $3.28B
• P/E Ratio: 475.50
• EPS: $0.02
• 52-Week High: $20.00
• 52-Week Low: $6.28

Market Sentiment

Telix Pharmaceuticals Limited currently has a Bullish sentiment score of 0.37.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is an innovative commercial-stage biopharmaceutical company dedicated to advancing the field of radiopharmaceuticals for the diagnosis and treatment of cancer and rare diseases. With its headquarters in North Melbourne, Australia, Telix operates in key markets including the United States, Belgium, Japan, and Switzerland, leveraging its expertise to deliver cutting-edge therapeutic and diagnostic solutions. The company's strategic focus on unmet medical needs unde...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Telix Pharmaceuticals Limited and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does TLX pay dividends?

Telix Pharmaceuticals Limited (TLX) does not currently pay a regular dividend.

What is TLX's P/E ratio?

Telix Pharmaceuticals Limited has a price-to-earnings (P/E) ratio of 475.50.

What is TLX's market cap?

Telix Pharmaceuticals Limited (TLX) has a market capitalization of $3.28B with a current stock price of $7.52.